文献速递膀胱癌与上尿路尿路上皮癌

蓝光膀胱镜监测非肌层浸润性膀胱癌:一项Meta分析

Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis.
PubMed 文献 · BJU Int · 2024-04-24

该Meta分析比较柔性蓝光膀胱镜(BLC)与柔性白光膀胱镜(WLC)在非肌层浸润性膀胱癌(NMIBC)监测中的价值,纳入10篇文献共1634例患者。在检测肿瘤复发方面,柔性BLC与WLC无差异(OR 1.08,95%CI 0.82-1.41);仅检测原位癌(CIS)时也无显著差异(OR 1.19,95%CI 0.82-1.69)。柔性BLC可检测更多可疑病灶和肿瘤复发,但假阳性率增加导致过度治疗。

要点

  • 柔性BLC与WLC检测NMIBC复发无差异(OR 1.08,95%CI 0.82-1.41)。
  • 仅检测CIS时两者也无显著差异(OR 1.19,95%CI 0.82-1.69)。
  • 柔性BLC检测所有类型复发的阳性预测值为72%,WLC为66%。

核心结论

  • 柔性BLC监测NMIBC较柔性WLC可检测更多可疑病灶和肿瘤复发,但假阳性率增加导致过度治疗。
  • 每进行100次柔性BLC操作可额外发现1例肿瘤复发,每50次可额外发现1例CIS复发。
  • 使用柔性BLC监测NMIBC患者时可考虑采用风险分层策略选择患者。

研究设计与样本

  • 系统检索主要数据库至2023年5月前发表的文章,遵循PRISMA声明。
  • 共纳入10篇文献,包含1634例患者进行定量合成。
  • 主要结局为柔性BLC与WLC在可疑膀胱病灶中检测膀胱癌复发的准确性。

主要发现

  • 检测疾病复发方面,柔性BLC与WLC无差异(OR 1.08,95%CI 0.82-1.41);风险差(RD)显示柔性BLC为1%,对应需治疗人数(NNT)为100。
  • 仅检测CIS的亚组Meta分析中,柔性BLC与WLC仍无显著差异(OR 1.19,95%CI 0.82-1.69),BLC的RD为2%(NNT=50)。
  • 柔性BLC和WLC检测所有类型复发的阳性预测值分别为72%和66%,检测CIS的阳性预测值分别为39%和29%。

关键数值与推荐

  • 柔性BLC与WLC检测复发:OR 1.08,95%CI 0.82-1.41,RD 1%,NNT 100。
  • 柔性BLC与WLC检测CIS:OR 1.19,95%CI 0.82-1.69,RD 2%,NNT 50。
  • 柔性BLC检测所有类型复发的阳性预测值为72%,WLC为66%。
  • 柔性BLC检测CIS的阳性预测值为39%,WLC为29%。

临床怎么用

  • 作者认为,柔性BLC监测NMIBC可检测更多可疑病灶和肿瘤复发,但假阳性率增加导致过度治疗。
  • 作者指出,每进行100次和50次柔性BLC操作可分别额外发现1例肿瘤复发和1例CIS复发。
  • 作者建议,使用柔性BLC监测NMIBC患者时可考虑采用风险分层策略选择患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the value of flexible blue-light cystoscopy (BLC) vs flexible white-light cystoscopy (WLC) in the surveillance setting of non-muscle-invasive bladder cancer (NMIBC). METHODS: All major databases were searched for articles published before May 2023 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The primary outcome was the accuracy of flexible BLC vs WLC in detecting bladder cancer recurrence among suspicious bladder lesions. RESULTS: A total of 10 articles, comprising 1634 patients, were deemed eligible for the quantitative synthesis. In the meta-analysis focusing on the detection of disease recurrence, there was no difference between flexible BLC and WLC (odds ratio [OR] 1.08, 95% confidence interval [CI] 0.82-1.41)]; the risk difference (RD) showed 1% of flexible BLC, corresponding to a number needed to treat (NNT) of 100. In the subgroup meta-analysis of detection of carcinoma in situ (CIS) only, there was again no significant difference between flexible BLC and WLC (OR 1.19, 95% CI 0.82-1.69), BLC was associated with a RD of 2% (NNT = 50). The positive predictive values for flexible BLC and WLC in detecting all types of recurrence were 72% and 66%, respectively, and for CIS they were 39% and 29%, respectively. CONCLUSION: Surveillance of NMIBC with flexible BLC could detect more suspicious lesions and consequently more tumour recurrences compared to flexible WLC, with a increase in the rate of false positives leading to overtreatment. A total of 100 and 50 flexible BLC procedures would need to be performed to find on additional tumor and CIS recurences, respectively. A risk-stratified strategy for patient selection could be considered when using flexible BLC for the surveillance of NMIBC patients.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Sari Motlagh R, Ghoreifi A, Yanagisawa T, et al. Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis. BJU Int. 2024. PMID: 38658172. doi:10.1111/bju.16364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。